The Brand Name LERKA Has Generic Salt :: Lercanidipine
LERKA Is From Company Piramal Hc. Priced :: Rs. 51.96/87.83
LERKA have Lercanidipine is comes under Sub class Anti Hypertensives of Main Class Cardiovascular System
Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hypertensives
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Mild to moderate essential hypertension, Stroke prevention.
Drug Dose ::
Adult: PO As HCl: 10 mg once daily, increase to 20 mg daily after 2 wk if needed. Use in the elderly: The recommended dosage is 10 mg orally once a day at least 15 minutes before meals; the dose may be increased to 20 mg depending on the individual patient’s response. Use in children: Since there is no clinical data in patients under the age of 18 years, use in children is not currently recommended. Use in renal or hepatic dysfunction: Special care should be exercised in patients with mild to moderate renal or hepatic dysfunction. Dosage above 20 mg daily must be approached with caution. Lercanidipine is not recommended for use in patients with severe hepatic or renal dysfunction.
Severe hepatic or renal impairment; aortic stenosis, unstable angina, uncontrolled heart failure, within 1 mth of MI; and known hypersensitivity to any dihydropyridine. Lercanidipine should not be taken with grapefruit juice. lactation, pregnancy.
Drug Precautions ::
Left ventricular dysfunction, sick sinus syndrome (if pacemaker not fitted), left ventricular dysfunction and ischaemic heart disease.
Drug Side Effects ::
Tachycardia, oedema, flushing, headache, dizziness, asthenia, rash, diarrhoea, polyuria, palpitations, hypotension, drowsiness, myalgia.
Pregnancy category ::
Drug Mode of Action ::
Lercanidipine is a dihydropyridine calcium-channel blocker which acts by inhibiting the influx of calcium ions through the slow channels of the vascular smooth muscle and myocardium during depolarization. Its main effect is vasodilatation because it has greater selectivity for vascular smooth muscle than cardiac smooth muscle.
Drug Interactions ::
Plasma concentration reduced by inducers of CYP3A4 eg rifampicin, phenytoin, carbamazepine. Bioavailability also reduced by metoprolol and possibly propranolol. Plasma concentrations increased by inhibitors of CYP3A4 eg imidazole antifungals, erythromycin, ritonavir, fluoxetine. Alcohol may potentiate vasodilating effect. Potentially Fatal: Significantly increased plasma levels of both lercanidipine and ciclosporin when administered together.